Tradestie Institutional Equity Comparison Engine

LXRX vs AQST โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LXRX Overall Edge

LXRX Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lexicon Pharmaceuticals, Inc. (LXRX) driven by superior Momentum & Technical, Options & Structure while AQST counters with relative strength in Growth & Margin. Fundamentally, LXRX trades at N/M Forward P/E with -147.4% operating margin (-20.7% YoY revenue) versus AQST at N/M Forward P/E and -114.1% operating margin (-41.0% YoY). In options structure, LXRX sits in BREAKDOWN (59th %ile IV; Dealer Gamma Walls on Pro) against AQST sits in BREAKDOWN (64th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
LXRX N/M vs AQST N/M Fwd P/E
Growth & Margin Winner AQST
Op Margin -147.4% vs -114.1% ยท YoY -20.7% vs -41.0%
Momentum & Technical Winner LXRX
1Y +5.5% vs -40.6% ยท 52W Pos 27% vs 14%
Options & Structure Winner LXRX
BREAKDOWN (59th %ile IV) vs BREAKDOWN (64th %ile IV)
LXRX NASDAQ
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Preparations
$1.53
-8.38% 1D
Market Cap $743.5M
1M Return +2.68%
1Y Return +5.52%
Forward P/E N/M
Unified AI Score
48.7 / 100 HOLD
Tech 25.0 Fund 49.0 Flow 69.0 Mom 64.0
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
1M Return -16.22%
1Y Return -40.65%
Forward P/E N/M
Unified AI Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LXRX +5.52% AQST -40.65% Spread: +46.17 pp (LXRX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LXRX Revenue AQST Revenue LXRX Op. Margin AQST Op. Margin Margin Edge
FY2018 $30M $70M -388.5% -72.6% AQST
FY2019 $30M $50M 437.5% -100.1% LXRX
FY2020 $20M $50M -204.2% -93.6% AQST
FY2021 N/A $50M N/A -68.2% AQST
FY2022 N/A $50M N/A -88.2% AQST
FY2023 $0M $50M -15473.0% -29.9% AQST
FY2024 $10M $60M -3284.7% -53.5% AQST
FY2025 $50M $40M -98.2% -159.5% LXRX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LXRX (4) vs AQST (4)
Institutional Metric LXRX AQST Criterion Row Winner
Market Capitalization Scale $743.5M $465.7M Larger Scale LXRX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -20.7% -41.0% Higher Growth LXRX
Operating Margin (TTM) Profitability -147.4% -114.1% Higher Margin AQST
Net Profit Margin Profitability -161.8% -162.3% Higher Margin LXRX
Return on Equity (ROE) Capital Efficiency -43.9% 0.0% Higher ROE AQST
52-Week Range Position Momentum 27% ($1โ€“$3) 14% ($3โ€“$7) Stronger Trend LXRX
Beta / 30D Volatility Risk Regime 0.85ฮฒ ยท 69% Vol 0.89ฮฒ ยท 56% Vol Lower Realized Risk AQST
Unified Institutional Score Composite Signal 48.7 / 100 (HOLD) 62.9 / 100 (BUY) Higher Composite AQST

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LXRX vs AQST Buy Guide
LXRX BREAKDOWN
102d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 59th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live LXRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AQST BREAKDOWN
61d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 64th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live AQST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LXRX nor AQST registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.